Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently.

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Its portfolio of approved drugs now features Casgevy, which targets a pair of rare blood diseases, and Journavx, a non-opioid medicine for acute pain. These will contribute to Vertex's growth.